Fecal Microbiota Transplantation in Recurrent or Refractory Clostridium Difficile Colitis
Status:
Unknown status
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The host gastrointestinal microbiota is significantly influenced by antibiotic treatment
which might favor Clostridium difficile infection (CDI), a frequent cause of community- and
hospital-acquired, potentially life-threatening diarrhoea. CDI is followed by recurrence in
19-35% of patients despite adequate first line antimicrobial therapy. Currently there is no
standardized therapy of recurrent or refractory CDI, but recent studies show remarkable
effects of fecal microbiota transplantation (FMT).
In the current project, we aim to ideally match host and donor for FMT success in recurrent
or refractory CDI. We will establish a clinical standard operating protocol for FMT, we will
evaluate its safety and efficacy, and the patient acceptance and quality of life before and
after FMT. We will analyse persistence of the donor microbiota within the recipient, define
predictive clinical recipient and donor factors for FMT success and correlate them with
microbial host and donor metagenomics.
We hypothesize that our work will yield novel, individualized strategies for recurrent or
refractory CDI. In perspective, our results may be expanded to treatment of other inflammory
bowel diseases.